Full-Time

Organ Health Specialist

Confirmed live in the last 24 hours

Natera

Natera

1,001-5,000 employees

Biotechnology firm specializing in genetic testing

Compensation Overview

$180k - $200kAnnually

Senior

Company Historically Provides H1B Sponsorship

Boston, MA, USA

The territory covers Boston, MA and surrounding area.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Sales
Requirements
  • Bachelor’s Degree or equivalent educational background.
  • A minimum of 6 years of progressive sales experience, ideally within the diagnostic or lab-developed test industry.
  • Proven track record of closing sales, building client relationships, and driving revenue growth.
  • Existing relationships with key opinion leaders (KOLs) in nephrology or specialty medicine.
  • Knowledge of academic medical systems and large hospital systems (IDNs) related to nephrology or specialty medicine.
  • Travel up to 50% - 75% within territory.
Responsibilities
  • Achieve and exceed performance goals through effective sales strategies, client relationship building, and territory management.
  • Drive market adoption of Natera’s products, contributing to successful product launches and market expansion.
  • Serve as a local expert on Natera’s technology and services, representing the company with professionalism and technical expertise.
  • Develop and execute tailored local business plans to achieve sales objectives and maximize available resources.

Natera focuses on genetic testing and diagnostics, utilizing cell-free DNA (cfDNA) testing to analyze DNA fragments in the blood for cancer detection and monitoring. Their services include the Signatera test for cancer patients, organ health assessments for transplant patients, and various tests for women's health, such as prenatal screening and hereditary cancer risk evaluation. Natera stands out by providing specialized testing services directly to healthcare providers and patients, often with insurance reimbursement, along with remote genetic counseling. The company's goal is to improve patient care through advanced genetic testing solutions that facilitate informed medical decisions.

Company Size

1,001-5,000

Company Stage

IPO

Total Funding

$149.9M

Headquarters

Austin, Texas

Founded

2004

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased adoption of liquid biopsy techniques boosts demand for Natera's cfDNA tests.
  • AI integration enhances accuracy of Natera's genetic tests, improving patient outcomes.
  • Telehealth expansion aligns with Natera's remote genetic counseling services, broadening their reach.

What critics are saying

  • Hindenburg's report accuses Natera of deceptive practices, risking legal and reputational issues.
  • CFO's stock sale may signal internal concerns about Natera's future performance.
  • Reliance on insurance reimbursements poses a risk if policies or rates change.

What makes Natera unique

  • Natera specializes in cell-free DNA testing for prenatal and cancer diagnostics.
  • The company offers the unique Signatera test for personalized cancer monitoring.
  • Natera's Prospera Heart test uses a novel Donor Quantity Score for transplant rejection detection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible medical plans

Investment options

Time off

Workplace perks

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

9%
Financial Modeling Prep
Feb 28th, 2025
Lantheus Holdings, Inc. (NASDAQ:LNTH) Demonstrates Strong Capital Efficiency

Lantheus competes with other companies in the medical and pharmaceutical industries, such as ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.

BioSpace
Feb 19th, 2025
Natera To Report Its Fourth Quarter And Full Year Results On February 27, 2025

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its fourth quarter and year ended Dec. 31, 2024, after the market closes on Feb. 27, 2025. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m

MarketBeat
Nov 24th, 2024
Alpha DNA Investment Management LLC Invests $505,000 in Natera, Inc. (NASDAQ:NTRA)

Alpha DNA Investment Management LLC invests $505,000 in Natera, Inc. (NASDAQ:NTRA).

MarketBeat
Sep 22nd, 2024
Delap Wealth Advisory LLC Makes New $454,000 Investment in Natera, Inc. (NASDAQ:NTRA)

Delap Wealth Advisory LLC makes new $454,000 Investment in Natera, Inc. (NASDAQ:NTRA).

Investing.com
Jul 2nd, 2024
Natera CFO sells over $539k in company stock

In other recent news, Natera Inc. has launched the DECIPHER trial for gastroesophageal adenocarcinoma (EGC) treatment, utilizing its molecular residual disease (MRD) test, Signatera.